This observation demonstrates, on the one hand, that CD73+ cancer cells are sensitive to 22E6 treatment but, on the other hand, corroborates the clinical problem of resistant immune escape variants induced by cancer monotherapies. This evidence concerns the gene NT5E and cancer.